Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMA Calls For Visual Warnings Among Measures To Restrict Valproate Use

Executive Summary

The European Medicines Agency has recommended that EU member states should introduce further restrictions on the use of valproate-containing medicines to avoid the drug's exposure in pregnancy.

You may also be interested in...



France Steps Up Scrutiny Of Epilepsy Drug Risks In Pregnancy

The French health authorities are looking more widely at the actual or potential risks of using anti-epileptic medicines in pregnancy or in women of child bearing age. Valproate is a particular focus, but other drugs like topiramate and pregabalin are also in the frame.

Illegal Emissions Force Sanofi Production Stoppage

Sanofi is working on technical improvements after its Mourenx site in southwest France was found to be emitting illegally high levels of solvents. Production at the site is on hold.

EU Patients Decry Medical ‘Ignorance’ About Side-Effects Of Quinolones & Fluoroquinolones

At the European Medicines Agency's second ever public hearing on the safety of marketed medicines, patients gave an emotional account of how they battled with 'ignorance' within the EU medical community about the severely debilitating and potentially permanent side-effects of some broad-spectrum antibiotics.

Related Content

Topics

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel